secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2026-08-03T20:05:17+00:00
Accession:  0001193125-26-330537
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Therapeutics Q2 net loss $61.6M; Phase 3 EMPEROR enrollment complete at 162 patients
--------------------------------------------------------------------------------

- Net loss of $61.6M ($0.93 per share) vs $23.5M loss in Q2 2025; revenue fell to $9.3M from $13.8M.
- Cash, equivalents and marketable securities $420M (incl. $65.7M post-quarter ATM sale); funds operations to potential 2028 launch.
- Phase 3 EMPEROR study of zorevunersen enrolled 162 patients; data readout expected Q3 2027.
- Pre-NDA meeting with FDA scheduled H2 2026; rolling NDA submission to begin Q1 2027.
- Phase 1 OSPREY study of STK-002 for ADOA: sentinel cohort dosed, initial data anticipated H1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000119312526330537/0001193125-26-330537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000119312526330537/stok-20260803.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-330537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer